308 related articles for article (PubMed ID: 31092171)
1. Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?
Argollo MC; Allocca M; Furfaro F; Peyrin-Biroulet L; Danese S
Curr Pharm Des; 2019; 25(1):25-31. PubMed ID: 31092171
[TBL] [Abstract][Full Text] [Related]
2. New treatment options for inflammatory bowel diseases.
Verstockt B; Ferrante M; Vermeire S; Van Assche G
J Gastroenterol; 2018 May; 53(5):585-590. PubMed ID: 29556726
[TBL] [Abstract][Full Text] [Related]
3. Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease.
Wong U; Cross RK
Expert Opin Investig Drugs; 2019 May; 28(5):473-479. PubMed ID: 30884245
[TBL] [Abstract][Full Text] [Related]
4. Biologic therapy for inflammatory bowel disease.
Ardizzone S; Bianchi Porro G
Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab for the treatment of Crohn's disease.
Hansen T; Targownik LE
Expert Rev Gastroenterol Hepatol; 2016 Sep; 10(9):989-94. PubMed ID: 27450626
[TBL] [Abstract][Full Text] [Related]
6. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S
Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464
[TBL] [Abstract][Full Text] [Related]
7. Role of the IL23/IL17 Pathway in Crohn's Disease.
Schmitt H; Neurath MF; Atreya R
Front Immunol; 2021; 12():622934. PubMed ID: 33859636
[TBL] [Abstract][Full Text] [Related]
8. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.
Deepak P; Sandborn WJ
Gastroenterol Clin North Am; 2017 Sep; 46(3):603-626. PubMed ID: 28838418
[TBL] [Abstract][Full Text] [Related]
9. IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?
Ma C; Panaccione R; Khanna R; Feagan BG; Jairath V
Best Pract Res Clin Gastroenterol; 2019; 38-39():101604. PubMed ID: 31327402
[TBL] [Abstract][Full Text] [Related]
10. Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles?
Lightner AL; McKenna NP; Alsughayer A; Harmsen WS; Taparra K; Parker ME; Raffals LE; Loftus EV
Dis Colon Rectum; 2019 Nov; 62(11):1352-1362. PubMed ID: 31567927
[TBL] [Abstract][Full Text] [Related]
11. [Biologic therapies in chronic inflammatory bowel diseases].
Reenaers C; Louis E; Belaiche J
Rev Med Liege; 2009; 64(5-6):301-4. PubMed ID: 19642463
[TBL] [Abstract][Full Text] [Related]
12. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies.
Conrad MA; Kelsen JR
Curr Gastroenterol Rep; 2020 Jun; 22(8):36. PubMed ID: 32542562
[TBL] [Abstract][Full Text] [Related]
13. Targeting IL-23 in Crohn's disease.
Sedda S; Bevivino G; Monteleone G
Expert Rev Clin Immunol; 2018 Nov; 14(11):907-913. PubMed ID: 30223688
[TBL] [Abstract][Full Text] [Related]
14. Blockade of IL-23: What is in the Pipeline?
Parigi TL; Iacucci M; Ghosh S
J Crohns Colitis; 2022 May; 16(Supplement_2):ii64-ii72. PubMed ID: 35553666
[TBL] [Abstract][Full Text] [Related]
15. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
[TBL] [Abstract][Full Text] [Related]
16. Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease.
Verstockt B; Van Assche G; Vermeire S; Ferrante M
Expert Opin Biol Ther; 2017 Jan; 17(1):31-47. PubMed ID: 27817215
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
Carman N; Mack DR; Benchimol EI
Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
[TBL] [Abstract][Full Text] [Related]
18. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS
J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708
[TBL] [Abstract][Full Text] [Related]
19. Optimization of biologics to reduce treatment failure in inflammatory bowel diseases.
Bourchany A; Gilletta De Saint-Joseph C; Breton A; Barreau F; Mas E
Curr Opin Pharmacol; 2020 Oct; 54():51-58. PubMed ID: 32947075
[TBL] [Abstract][Full Text] [Related]
20. The role of biologics in the treatment of patients with inflammatory bowel disease.
Selinger CP; Carbery I; Al-Asiry J
Br J Hosp Med (Lond); 2018 Dec; 79(12):686-693. PubMed ID: 30526103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
